This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $518,754 to Magee-Womens Research Institute and Foundation to develop a bioadhesive vaginal film for extended release of multipurpose technology (MPT) antibodies. The goal is to create a film that can provide contraception and antiviral protection (against HIV and HSV) for up to 7 days from a single...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, is supporting the development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for the treatment of opioid use disorder (OUD). The $2,932,500 award to The Drug Delivery Company, LLC will fund the development of this 6-month buprenorphine implant, building upon the company's prior success with a 6-month bioabsorbable...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $702,000 to support a 3-year project aimed at optimizing the implementation of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention. The key objectives are to: 1) Identify barriers and facilitators to LAI-PrEP implementation, 2) Determine optimal implementation strategies in partnership with...
Hera Health Solutions Inc. received a $275,000 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program to develop a biodegradable contraceptive-releasing implant. The award aims to advance long-acting reversible contraception by creating an implant that delivers consistent hormone doses and does not require surgical removal. During the one-year period from May 1, 2023 to April 30, 2024, the company will characterize the drug delivery scaffold,...
This $380,692 Project Grant awarded by the National Institute of Child Health and Human Development (NICHD) under CFDA Program 93.865 (Child Health and Human Development Extramural Research) supports the development of an ultrapotent anti-sperm antibody construct for a non-hormonal contraceptive intravaginal ring. The funding will be used by Mucommune LLC, a biopharmaceutical company in Durham, North Carolina, to validate the safety and effectiveness of the LAMH10 antibody formulated into an...
This Project Grant award of $414,522, issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting the development of an ionic liquid-based nanoemulsion formulation containing a combination of antiretroviral drugs (dolutegravir and rilpivirine) for the transdermal treatment of pediatric HIV infection. The University of Arizona, the prime grantee, is leading the research to create a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,670,110 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Oak Crest Institute of Science to develop a novel, multi-compartment intravaginal ring for the prevention of genital herpes and unintended pregnancy. The project aims to integrate key innovations, including an antiviral peptide lead candidate effective against herpes simplex virus (HSV), human papillomavirus (HPV), and human...
The federal Project Grant award, R61AI188553, was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award totaling $2,207,322 aims to develop ultra-long-acting antiretroviral therapy (ART) formulations for the treatment of HIV-1 infection in pediatric populations. The approach involves transforming established daily oral pediatric ART regimens,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
This $715,041 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to understand real-world choices, preferences, and outcomes related to the roll-out of oral and long-acting injectable PrEP (pre-exposure prophylaxis) among women in Malawi. The study, titled "Better Info on Women's PrEP Choices and Outcomes in Malawi", has three specific aims: 1) Evaluate longitudinal patterns of oral...